Trial Profile
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Selonsertib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
- 10 Nov 2015 New trial record